Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2004-04-06 Major Shareholding Noti…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 2
Major Shareholding Notification
2004-04-06 English
FORM 8-K DATED 3/31/04
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 31, 2004. It announces an agreement terminating a collaboration between Targeted Genetics Corporation and Elan Corporation plc. The document includes a press release and a termination agreement as exhibits. There are no financial statements or detailed financial data presented, and the document is relatively short (3206 characters). The content is an announcement of an event rather than a full financial report or detailed management discussion. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2004-04-06 English
Director's Dealing 2004
Director's Dealing
2004-04-02 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2004-03-24 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 17, 2004. It announces the initiation of a Phase I clinical trial and includes a press release as Exhibit 99.1. The document does not contain financial statements, detailed financial data, or management discussion and analysis. It is a regulatory announcement of a corporate event rather than a full financial report or earnings release. The length is short (2379 characters), and it primarily serves as a notification of an event and includes a press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2004-03-18 English
FORM 10-K
Annual Report FY 2003
2004-03-11 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.